EchoGo® Heart Failure vs Reveal LINQ Insertable Cardiac Monitor
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A is an AI platform designed for rapid diagnosis of Heart Failure with preserved Ejection Fraction (HFpEF) by analyzing echocardiograms, providing clinical decision support. In contrast, Tool B is an AI-enhanced insertable cardiac monitor focused on long-term, continuous ECG monitoring to detect and reduce false alerts for conditions like atrial fibrillation and syncope. While both utilize AI in cardiology, they address distinct clinical needs: one for diagnostic imaging analysis and the other for prolonged physiological monitoring.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Heart Failure is an AI platform designed to analyze routine echocardiograms for the detection of Heart Failure with preserved Ejection Fraction (HFpEF). The Reveal LINQ Insertable Cardiac Monitor (ICM) is intended for long-term, continuous subcutaneous ECG monitoring to detect conditions such as atrial fibrillation and syncope.
EchoGo Heart Failure uses AI to analyze existing echocardiogram video clips to identify radiomic signatures of HFpEF. In contrast, the Reveal LINQ ICM is an implantable device that continuously records subcutaneous ECG data, utilizing AccuRhythm AI algorithms to reduce false alerts for conditions like AF and Pause.
EchoGo Heart Failure is a cloud-based platform that integrates with existing IT stacks and DICOM workflows, analyzing echo clips and delivering automated reports within 20 minutes, with no direct patient interaction beyond the initial echocardiogram. The Reveal LINQ ICM is an implanted device that transmits data remotely to a cloud-based platform (CareLinku2122 network) via a patient's smartphone app or home communicator, requiring patient engagement for data transmission.
EchoGo Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers. Pricing for the Reveal LINQ ICM is not publicly disclosed and requires direct consultation with Medtronic sales representatives.
EchoGo Heart Failure's AI is clinically validated for HFpEF detection, demonstrating 90% sensitivity and 86% specificity. The Reveal LINQ ICM incorporates AccuRhythm AI algorithms specifically designed to reduce false alerts for atrial fibrillation and pauses, thereby enhancing diagnostic yield.
EchoGo Heart Failure provides insights from echocardiogram analysis within 20 minutes. The Reveal LINQ ICM offers continuous, long-term subcutaneous ECG monitoring with a battery longevity of 4.5 years at nominal settings.